B-cell Lymphoma Clinical Trials in Houston, Texas

7 studies are recruiting for b-cell lymphoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

   To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05615636 on ClinicalTrials.gov

2. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

   The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Md Anderson Cancer Center, Houston, Texas

   Locations

   155 in total

   Run by

   BeOne Medicines

   See if you can join NCT06742996 on ClinicalTrials.gov

3. A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

   The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with sep…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   49 in total

   Run by

   BeOne Medicines

   See if you can join NCT06634589 on ClinicalTrials.gov

4. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

   The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   51 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07101328 on ClinicalTrials.gov

5. A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

   To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06213311 on ClinicalTrials.gov

6. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

   The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

   Stage

   Phase 1

   Ages

   12 to 80

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05092451 on ClinicalTrials.gov

7. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Texas Children's Hospital, Houston, Texas

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov